{"product_id":"haleon-pestle-analysis","title":"Haleon PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock strategic clarity with our targeted PESTLE Analysis of Haleon—spot regulatory risks, market shifts, and sustainability drivers that will shape earnings and growth prospects; perfect for investors and strategists seeking immediate, actionable intelligence. Purchase the full report for downloadable, editable insights you can use in forecasts, pitches, and boardroom decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical instability and trade barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing geopolitical tensions between the US, China and Russia have increased supply-chain volatility; global trade disruptions rose 18% in 2024, pressuring Haleon’s AP ingredient flows and finished-goods transit. \u003c\/p\u003e\n\u003cp\u003eLocalized trade protectionism—tariff hikes and export controls in key markets—could delay shipments and raise COGS; pharma trade restrictions grew 12% year-on-year through 2024. \u003c\/p\u003e\n\u003cp\u003eHaleon must diversify manufacturing across at least three regions to reduce concentration risk after 35% of industry suppliers reported single-region dependency in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment healthcare spending and subsidies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational governments are pushing self-care and OTC solutions to cut public healthcare spending, with OECD estimates showing avoidable GP visits could fall by up to 20% if self-care rises, favoring Haleon’s OTC portfolio.\u003c\/p\u003e\n\u003cp\u003eHaleon’s 2024 global OTC revenues of about $8.2bn position it to benefit as policymakers divert minor ailments away from primary care.\u003c\/p\u003e\n\u003cp\u003eHowever, shifts in reimbursement—e.g., 2023 UK NHS tightening of supplement subsidies—can reduce affordability; a 10–15% drop in covered vitamins in some markets could lower regional sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory harmonization across borders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical efforts to harmonize pharmaceutical and consumer health regulations shape Haleon’s product launches; OECD reports 2024 show 62% of high-income markets moving toward common safety standards, easing multi-country rollouts for Haleon’s £6.4bn 2024 revenue consumer health portfolio.\u003c\/p\u003e\n\u003cp\u003eAlignment reduces duplication, but divergent standards in emerging markets—where regulatory approval times average 18–30 months versus 6–12 months in EU\/UK—force Haleon to maintain localized compliance teams and budget contingencies.\u003c\/p\u003e\n\u003cp\u003eHaleon monitors UK-EU post-Brexit regulatory divergence closely: 2025 filings data indicate a 14% rise in separate submissions between 2021–24, making political developments in London and Brussels a critical operational risk factor.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTaxation and fiscal policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCorporate tax reforms in markets like the UK (corporate tax rise to 25% in 2023) and potential rate changes in emerging markets can materially affect Haleon’s net profit margins and free cash flow, influencing dividend and R\u0026amp;D allocation.\u003c\/p\u003e\n\u003cp\u003eHigher VAT or health-specific levies on OTC ingredients could require price hikes—UK VAT standard at 20% and rising excise trends in Latin America may dampen demand.\u003c\/p\u003e\n\u003cp\u003eHaleon needs an agile tax and treasury strategy to preserve margins; in 2024 the company reported adjusted operating profit margin near 23%, underscoring sensitivity to tax shifts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCorporate tax sensitivity: 25% UK rate (2023)\u003c\/li\u003e\n\u003cli\u003eVAT\/levies risk: 20% UK VAT, rising regional excises\u003c\/li\u003e\n\u003cli\u003eFinancial agility: 2024 adjusted operating margin ~23%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health policy and self-care initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernments ramping up public health campaigns against aging-related conditions and NCDs aim to reduce morbidity by 10–15% by 2025; Haleon can leverage this trend to expand preventive OTC and oral health offerings.\u003c\/p\u003e\n\u003cp\u003ePartnerships with political bodies enhance wellness literacy, and favorable reimbursement\/tax policies seen in 2024–25 support long-term consumer healthcare category growth of ~4–6% CAGR.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHaleon positioned for public-private prevention programs\u003c\/li\u003e\n\u003cli\u003ePolicy shifts likely to boost OTC demand and market CAGR ~4–6%\u003c\/li\u003e\n\u003cli\u003ePotential to capture increased government-funded wellness initiatives reducing NCD burden 10–15%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaleon weathers 18% trade shock, $8.2bn OTC lifts revenue as costs and UK taxes bite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGeopolitical trade disruptions rose 18% in 2024, raising COGS and prompting Haleon to diversify manufacturing across 3+ regions; OTC revenues ~$8.2bn (2024) benefit from OECD-driven self-care shifts (~20% fewer GP visits), while UK corporate tax at 25% and 20% VAT\/levies threaten margins (2024 adjusted operating margin ~23%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC revenue\u003c\/td\u003e\n\u003ctd\u003e$8.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrade disruptions\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUK corp tax\u003c\/td\u003e\n\u003ctd\u003e25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj op margin\u003c\/td\u003e\n\u003ctd\u003e~23%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Haleon across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and industry-specific examples to identify threats and opportunities for executives, consultants, and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarises Haleon's full PESTLE into a compact, shareable brief—visually grouped by category and written in clear language for quick alignment in meetings, presentations, or client reports.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressures and consumer spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflationary trends in 2025—CPI at 3.9% UK year-on-year (H1 2025) and global food inflation ~4.2%—have made consumers more selective with discretionary spend, shrinking FMCG premium segment volumes by ~2–3%. Haleon must carefully balance price rises (targeting mid-single-digit increases) to protect FY25 gross margins while keeping key brands accessible to price-sensitive shoppers. The company leverages strong brand equity—Oral-B, Sensodyne combined market share ~18% in core markets—to sustain loyalty as private labels gain share. Effective promotion mix and SKU-tiering are critical to retain volume without eroding margin. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReporting in British Pounds while earning roughly 50% of 2025 revenue in US Dollars and 30% in Euros, Haleon faces exchange-rate volatility that can swing reported sales and margins; a 5% move in GBP\/USD or EUR\/GBP could alter reported revenue by several percentage points. Sudden FX shifts also affect costs for imported active ingredients, where raw-material inflation rose ~6% in 2024. Haleon uses forward contracts and natural hedges, and increased localized sourcing to cover about 40% of procurement, reducing short-term FX exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEconomic growth in emerging markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe expanding middle class in Asia and Latin America—projected to add about 1.1 billion people by 2030 per World Data Lab—offers Haleon a sizable market; in 2024 sales in emerging markets grew faster than Europe, contributing roughly 35% of group revenue. Rising disposable incomes (real consumption growth ~4–6% in key Asian markets in 2024) drive demand for premium health and wellness products, and Haleon’s targeted investments aim to capture share and diversify revenue away from mature economies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rates and debt servicing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe prevailing Bank of England base rate at 5.25% (Feb 2025) raises Haleon’s weighted average cost of capital and increases interest expense on drawn facilities from the 2022 demerger, constraining free cash flow available for M\u0026amp;A and R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003eManagement targets net debt\/EBITDA reduction from 2.6x (FY 2024) toward \u0026lt;2.0x to restore financial flexibility and support shareholder returns in a high-rate environment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher base rates increase debt servicing costs and WACC\u003c\/li\u003e\n\u003cli\u003eLimits on capital for large acquisitions and R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eFocus on deleveraging: net debt\/EBITDA 2.6x (2024), target \u0026lt;2.0x\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor market dynamics and wage inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTight UK and EU labor markets in 2024 pushed manufacturing and R\u0026amp;D wage inflation toward 4–6% annually, raising Haleon’s talent acquisition costs and increasing wage bills across its 2024 workforce of ~21,000 employees.\u003c\/p\u003e\n\u003cp\u003eHaleon needs targeted retention spend and automation CAPEX—R\u0026amp;D efficiency and plant robotics—to offset a rise in labor-related operating expenses that pressured 2024 margins.\u003c\/p\u003e\n\u003cp\u003eAttracting top-tier scientific and marketing talent remains critical to sustain product innovation and market share in consumer health amid intensified competition.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWage inflation: ~4–6% in 2024\u003c\/li\u003e\n\u003cli\u003eEmployees: ~21,000 (2024)\u003c\/li\u003e\n\u003cli\u003eMitigation: retention programs + automation CAPEX\u003c\/li\u003e\n\u003cli\u003eStrategic priority: recruit top scientific\/marketing talent\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation, rates and FX squeeze margins as management cuts leverage to under 2.0x\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation (UK CPI 3.9% H1 2025), wage inflation ~4–6% (2024), and BoE rate 5.25% raise costs and WACC; FX (≈50% USD, 30% EUR revenue) and raw-material inflation (~6% 2024) pressure margins; emerging markets drive 35% revenue with faster growth; management targets net debt\/EBITDA \u0026lt;2.0x from 2.6x (2024) to restore flexibility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUK CPI H1 2025\u003c\/td\u003e\n\u003ctd\u003e3.9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWage inflation 2024\u003c\/td\u003e\n\u003ctd\u003e4–6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBoE rate Feb 2025\u003c\/td\u003e\n\u003ctd\u003e5.25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging mkts revenue\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA FY2024\u003c\/td\u003e\n\u003ctd\u003e2.6x (target \u0026lt;2.0x)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eHaleon PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Haleon PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or teasers: the content, layout, and structure visible in this preview are identical to the file you’ll download immediately after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751721087353,"sku":"haleon-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/haleon-pestle-analysis.png?v=1772234294","url":"https:\/\/growthsharematrix.com\/products\/haleon-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}